✦ LIBER ✦

A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy

✍ Scribed by David S. Ettinger; Peter D. Eisenberg; David Fitts; Carl Friedman; Karen Wilson-Lynch; Karen Yocom

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 848 KB
Volume: 78
Category: Article
ISSN: 0008-543X
DOI: 10.1002/(sici)1097-0142(19960701)78:1<144::aid-cncr20>3.0.co;2-z

No coin nor oath required. For personal study only.

✦ Synopsis

The purpose of this study was to define an optimal administration schedule of granisetron for patients receiving moderately ernetogenic chemotherapy by comparing the antiemetic efficacy and safety of 2 mg of the drug administered orally.

METHODS.

In this double-blind, randomized, parallel study, 2-dose regimens of oral granisetron were evaluated in 697 adult cancer patients. Patients were stratified by gender and randomized to receive 2 mg oral granisetron, either as a divided dose given 1 hour prior to chemotherapy and 12 hours after the start of chemotherapy, or as a single dose 1 hour prior to chemotherapy at Cycle 1. The primary efficacy endpoints assessed were the percentage of patients with complete response (no

📜 SIMILAR VOLUMES

Randomized, double blind, dose-response

Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy

✍ Edward B Rubenstein; Richard J. Gralla; John D. Hainsworth; Paul J. Hesketh; Tho 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## BACKGROUND. This double blind parallel group study assessed the acute antiemetic

Open-label comparison of the antiemetic

Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy

✍ Coppes, Max J.; Lau, Robert; Ingram, Lewis C.; Wiernikowski, John T.; Grant, Ron 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Background. Nausea and vomiting are among the most unpleasant adverse side effects of cancer therapy. Procedure. An open-label dose-escalation study was conducted to assess the appropriate intravenous dose of dolasetron for pediatric patients undergoing chemotherapy. Patients received dolasetron in

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre